Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells

Dirk Kuck, Thomas Caulfield, Frank Lyko, Jose L. Medina-Franco

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Enzymes involved in the epigenetic regulation of the genome represent promising starting points for therapeutic intervention by small molecules, and DNA methyltransferases (DNMT) are emerging targets for the development of a new class of cancer therapeutics. In this work, we present nanaomycin A, initially identified by a virtual screening for inhibitors against DNMT1, as a compound inducing antiproliferative effects in three different tumor cell lines originating from different tissues. Nanaomycin A treatment reduced the global methylation levels in all three cell lines and reactivated transcription of the RASSF1A tumor suppressor gene. In biochemical assays, nanaomycin A revealed selectivity toward DNMT3B. To the best of our knowledge, this is the first DNMT3B-selective inhibitor identified to induce genomic demethylation. Our study thus establishes the possibility of selectively inhibiting individual DNMT enzymes.

Original languageEnglish (US)
Pages (from-to)3015-3023
Number of pages9
JournalMolecular Cancer Therapeutics
Volume9
Issue number11
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Tumor Suppressor Genes
Methyltransferases
Neoplasms
DNA
Enzymes
Tumor Cell Line
Epigenomics
Methylation
Genome
Cell Line
Therapeutics
nanaomycin A

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. / Kuck, Dirk; Caulfield, Thomas; Lyko, Frank; Medina-Franco, Jose L.

In: Molecular Cancer Therapeutics, Vol. 9, No. 11, 11.2010, p. 3015-3023.

Research output: Contribution to journalArticle

@article{ce91b5bdd9054e88b31a69d1a6d6f226,
title = "Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells",
abstract = "Enzymes involved in the epigenetic regulation of the genome represent promising starting points for therapeutic intervention by small molecules, and DNA methyltransferases (DNMT) are emerging targets for the development of a new class of cancer therapeutics. In this work, we present nanaomycin A, initially identified by a virtual screening for inhibitors against DNMT1, as a compound inducing antiproliferative effects in three different tumor cell lines originating from different tissues. Nanaomycin A treatment reduced the global methylation levels in all three cell lines and reactivated transcription of the RASSF1A tumor suppressor gene. In biochemical assays, nanaomycin A revealed selectivity toward DNMT3B. To the best of our knowledge, this is the first DNMT3B-selective inhibitor identified to induce genomic demethylation. Our study thus establishes the possibility of selectively inhibiting individual DNMT enzymes.",
author = "Dirk Kuck and Thomas Caulfield and Frank Lyko and Medina-Franco, {Jose L.}",
year = "2010",
month = "11",
doi = "10.1158/1535-7163.MCT-10-0609",
language = "English (US)",
volume = "9",
pages = "3015--3023",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells

AU - Kuck, Dirk

AU - Caulfield, Thomas

AU - Lyko, Frank

AU - Medina-Franco, Jose L.

PY - 2010/11

Y1 - 2010/11

N2 - Enzymes involved in the epigenetic regulation of the genome represent promising starting points for therapeutic intervention by small molecules, and DNA methyltransferases (DNMT) are emerging targets for the development of a new class of cancer therapeutics. In this work, we present nanaomycin A, initially identified by a virtual screening for inhibitors against DNMT1, as a compound inducing antiproliferative effects in three different tumor cell lines originating from different tissues. Nanaomycin A treatment reduced the global methylation levels in all three cell lines and reactivated transcription of the RASSF1A tumor suppressor gene. In biochemical assays, nanaomycin A revealed selectivity toward DNMT3B. To the best of our knowledge, this is the first DNMT3B-selective inhibitor identified to induce genomic demethylation. Our study thus establishes the possibility of selectively inhibiting individual DNMT enzymes.

AB - Enzymes involved in the epigenetic regulation of the genome represent promising starting points for therapeutic intervention by small molecules, and DNA methyltransferases (DNMT) are emerging targets for the development of a new class of cancer therapeutics. In this work, we present nanaomycin A, initially identified by a virtual screening for inhibitors against DNMT1, as a compound inducing antiproliferative effects in three different tumor cell lines originating from different tissues. Nanaomycin A treatment reduced the global methylation levels in all three cell lines and reactivated transcription of the RASSF1A tumor suppressor gene. In biochemical assays, nanaomycin A revealed selectivity toward DNMT3B. To the best of our knowledge, this is the first DNMT3B-selective inhibitor identified to induce genomic demethylation. Our study thus establishes the possibility of selectively inhibiting individual DNMT enzymes.

UR - http://www.scopus.com/inward/record.url?scp=78649676706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649676706&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0609

DO - 10.1158/1535-7163.MCT-10-0609

M3 - Article

VL - 9

SP - 3015

EP - 3023

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -